Gabrielle Drevet

Dr. Gabrielle Drevet

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
GDGabrielle Drevet
Gabrielle Drevet
CSCollaud Stéphane
Collaud Stéphane
FTFrançois Tronc
François Tronc
NGNicolas Girard
Nicolas Girard
JMJean-Michel Maury
Jean-Michel Maury
Thymic epithelial tumors (TETs) belong to orphan oncology. The incidence of TETs is about 1.3–3.2 cases per million worldwide. Following pathology, evolution and prognosis are variable. The World Health Organization classification distinguishes thymomas and thymic carcinomas. TETs are composed of thymic epithelial tumoral cells and normal lymphocytes. The mean age at diagnosis is 50–60 years-old. There are no identified risk factors. TETs are frequently associated with paraneoplastic syndromes as myasthenia gravis. The complete R0 surgical resection is the most significant prognosis factor on survival. In 2010, the French National Institute of Cancer labeled the RYTHMIC network as a specific tumor board including thoracic surgeons, oncologist, and radiation therapist to define standard of care for the management of TETs. The aim of the review was to update knowledge to optimize the standard of care.

1 January 2020 in Lung Cancer
Verified
Journal Article
Closed access
GDGabrielle Drevet
Gabrielle Drevet
MDMichaël Duruisseaux
Michaël Duruisseaux
JMJean-Michel Maury
Jean-Michel Maury
BRBenjamin Riche
Benjamin Riche
RGRenaud Grima
Renaud Grima
FTFrançois Tronc
François Tronc

21 March 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JMJean-Michel Maury
Jean-Michel Maury
CVClaire Merveilleux du Vignaux
Claire Merveilleux du Vignaux
GDGabrielle Drevet
Gabrielle Drevet
VZVirginie Zarza
Virginie Zarza
LCLara Chalabreysse
Lara Chalabreysse
Caroline LerouxCaroline Leroux
Caroline Leroux
The pathogenesis of thymic epithelial tumors remains poorly elucidated. The PIK3/Akt/mTOR pathway plays a key role in various cancers; interestingly, several phase I/II studies have reported a positive effect of mTOR inhibitors in disease control in thymoma patients. A major limit for deciphering cellular and molecular events leading to the transformation of thymic epithelial cells or for testing drug candidates is the lack of reliable in vitro cell system. We analyzed protein expression and activation of key players of the Akt/ mTOR pathway namely Akt, mTOR, and P70S6K in eleven A, B and AB thymomas as well as in normal thymuses. While only Akt and phospho-Akt were expressed in normal thymuses, both Akt and mTOR were activated in thymomas. Phospho-P70S6K was expressed in all thymic tumors whatever their subtypes, and absent in normal thymus. Interestingly, we report the activation of Akt, mTOR and P70S6 proteins in primary thymic epithelial cells maintained for short period of time after their derivation from seven AB and B thymomas. Finally, we showed that rapamycin (100 nM) significantly reduced proliferation of thymoma- derived epithelial cells without inducing cell death. Our results suggest that the activation of the Akt/ mTOR pathway might participate to the cell proliferation associated with tumor growth. Ultimately, our data enhance the potential role of thymic epithelial cells derived from tissue specimens for in vitro exploration of molecular abnormalities in rare thymic tumors.

1 July 2021 in Lung Cancer
Verified
Journal Article
Closed access
HCHugo Clermidy
Hugo Clermidy
JMJean-Michel Maury
Jean-Michel Maury
SCStéphane Collaud
Stéphane Collaud
GDGabrielle Drevet
Gabrielle Drevet
MGMarylise Ginoux
Marylise Ginoux
FTFrançois Tronc
François Tronc

14 October 2022 in Cancers
Verified
Journal Article
Open access
PDF file
BCBenjamin Chappuy
Benjamin Chappuy
GDGabrielle Drevet
Gabrielle Drevet
HCHugo Clermidy
Hugo Clermidy
PRPascal Rosamel
Pascal Rosamel
MDMickael Duruisseaux
Mickael Duruisseaux
JMJean-Michel Maury
Jean-Michel Maury
Introduction: Stage IVa thymoma is a rare disease without a standard of care. Subtotal pleurectomy and HITHOC introduced in highly selected patients may provide interesting oncologic results. The purpose of this study was to distinguish de novo stage IVa tumors (DNT) from distant relapse (DR) with respect to post-operative and long-term outcomes to provide the procedure efficacy. Methods: From July 1997–December 2021, 40 patients with IVa pleural involvement were retrospectively analyzed. The surgical procedure was subtotal pleurectomy and HITHOC (cisplatin 50 mg/m2, mitomycin 25 mg/m2, 42 °C, 90 min). The post-operative outcome, disease-free interval (DFI) and overall survival (OS) were analyzed. Results: Mean age was 52 ± 12 years. B2 and B3 thymomas were preponderant (27; 67.5%). The median number of pleural nodes were nine (4–81) vs. five (1–36); p = 0.004 * in DNT and DR, respectively. Hospital mortality rate was 2.5%. There were four specific HITHOC complications (10%). DFI were 49 and 85 months (p = 0.02 *), OS were 94 and 118 months (NS), in DNT and DR, respectively. Conclusions: Subtotal pleurectomy with HITHOC in IVa offers satisfying results in highly selected patients, for both DNT and DR. Due to the disease rarity, multicentric studies are needed to define HITHOC as a standard of care.

7 September 2020 in Pleura and Peritoneum
Verified
Journal Article
Open access
PDF file
GDGabrielle Drevet
Gabrielle Drevet
JMJean-Michel Maury
Jean-Michel Maury
NBNaoual Bakrin
Naoual Bakrin
FTFrançois Tronc
François Tronc
Objectives: Malignant pleural effusion (MPE) is a devastating evolution of several malignancies. Pressurized intrathoracic aerosol chemotherapy (PITAC) might be a novel therapy option in MPE. Methods: PITAC is considered for patients with MPE with a performance status <2 and without other metastatic sites. General anesthesia is administered and a double-lumen bronchial tube is inserted. The patient is placed in a lateral decubitus position, and the operation is performed after ipsilateral lung exclusion. Two 12-mm balloon trocars are inserted—one in the seventh intercostal space in the mid-axillary line and one in the fifth intercostal space in the anterior axillary line. Extent of pleural disease and volume of MPE are documented. MPE is removed and parietal pleural biopsy are performed. An intrathoracic pressure of 12 mmHg CO 2 is established, and a combination of Cisplatin (10.5 mg/m 2 in a total volume of 150 cc NaCl 0.9%) and Doxorubicin (2.1 mg/m 2 in a total volume of 50 cc NaCl 0.9%) are aerosolized via nebulizer in the pleural cavity. Vital signs and nebulization are remote-controlled. After 30 min, the remaining toxic aerosol is exhausted using a closed surgical smoke evacuation system. A 24Fr chest tube is inserted in postero-apical position with continuous negative pressure of 20 cm H 2 O. When needed, PITAC may be repeated every six weeks in alternate with systemic chemotherapy. Results: In our hands, the technique above has shown to be feasible and safe. Conclusions: Further studies are needed to assess the potential symptomatic and oncological benefits of PITAC in MPE.